Breaking News Instant updates and real-time market news.

2020-12-02 16:23:14 SMTC Semtech $67.71 / -0.17 (-0.25%) 16:23 12/02/20 12/02 16:23 12/02/20 16:23	Semtech reports Q3 EPS 47c, consensus 46c Reports Q3 revenue $154.1M, consensus $149.83M. CEO Mohan Maheswaran stated, "We delivered Fiscal Q3 net sales that were at the upper-end of our guidance led by another quarterly record from our LoRa technology platforms and increasing smartphone demand. During the quarter we announced a collaboration with Amazon for its new Sidewalk network, further demonstrating the value that LoRa delivers to the emerging smart-home and consumer use cases. We believe the underlying fundamentals driving our growth engines in the Infrastructure, IoT and mobile platform markets remain strong and the Company remains well positioned for growth."	02 Dec
SMTC Semtech $67.71 / -0.17 (-0.25%) 11/30/20 B. Riley Securities Semtech price target raised to $83 from $72 at B. Riley Securities 11/25/20 Oppenheimer Semtech price target raised to $75 from $65 at Oppenheimer 08/27/20 B. Riley Securities Semtech price target raised to $72 from $65 at B. Riley FBR 08/27/20 Wells Fargo Semtech price target raised to $67 from $57 at Wells Fargo

2020-12-02 16:23:14

SMTC

Semtech

$67.71 / -0.17 (-0.25%)

16:23

12/02/20

12/02

16:23

12/02/20

16:23

Semtech reports Q3 EPS 47c, consensus 46c

Reports Q3 revenue $154.1M, consensus $149.83M. CEO Mohan Maheswaran stated, "We delivered Fiscal Q3 net sales that were at the upper-end of our guidance led by another quarterly record from our LoRa technology platforms and increasing smartphone demand. During the quarter we announced a collaboration with Amazon for its new Sidewalk network, further demonstrating the value that LoRa delivers to the emerging smart-home and consumer use cases. We believe the underlying fundamentals driving our growth engines in the Infrastructure, IoT and mobile platform markets remain strong and the Company remains well positioned for growth."

02
Dec

SMTC Semtech

$67.71 / -0.17 (-0.25%)

11/30/20 B. Riley Securities: Semtech price target raised to $83 from $72 at B. Riley Securities

11/25/20 Oppenheimer: Semtech price target raised to $75 from $65 at Oppenheimer

08/27/20 B. Riley Securities: Semtech price target raised to $72 from $65 at B. Riley FBR

08/27/20 Wells Fargo: Semtech price target raised to $67 from $57 at Wells Fargo

TODAY'S FREE FLY STORIES

Hot Stocks	Reading International trading resumes 10:57 01/19/21 01/19 10:57 01/19/21 10:57
Options	TJX put volume heavy and directionally bearish » 10:55 01/19/21 01/19 10:55 01/19/21 10:55 TJX TJX $67.52 / -0.985 (-1.44%) Bearish flow noted in TJX… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options TJX TJX $67.52 / -0.985 (-1.44%) 12/08/20 TJX raises quarterly dividend 13% to 26c per share 11/23/20 TJX chairman sells 77.9K shares of common stock 11/18/20 TJX expects higher incremental freight costs in Q4 11/18/20 TJX sees some pressure during peak shopping times in some stores TJX TJX $67.52 / -0.985 (-1.44%) 01/04/21 JPMorgan TJX price target raised to $74 from $70 at JPMorgan 12/30/20 Guggenheim TJX price target raised to $78 from $70 at Guggenheim 12/14/20 Citi strategist removes TJX from 'Recommended List' 12/11/20 Fly Intel: Top five analyst downgrades TJX TJX $67.52 / -0.985 (-1.44%) 11/18/20 TJX reports Q3 EPS 71c, consensus 40c 11/17/20 Notable companies reporting before tomorrow's open 11/17/20 Notable companies reporting before tomorrow's open 08/19/20 TJX reports Q2 EPS (18c), consensus (10c) TJX TJX $67.52 / -0.985 (-1.44%) 12/22/20 Overstock eyes potential brick-and-mortar partnerships, AdWeek says 08/22/20 These four stocks are Barron's plays on 'strange' back-to-school season TJX TJX $67.52 / -0.985 (-1.44%) 11/18/20 Fly Intel: Wall Street's top stories for Wednesday 11/18/20 Fly Intel: Wall Street's top stories at midday 11/18/20 Fly Intel: Pre-market Movers 08/19/20 Fly Intel: Wall Street's top stories for Wednesday TJX TJX $67.52 / -0.985 (-1.44%) 11/18/20 Unusually active option classes on open November 18th 10/28/20 TJX call volume above normal and directionally bullish 10/01/20 TJX call volume above normal and directionally bullish 09/24/20 TJX call volume above normal and directionally bullish
Conference/Events	Newborn Acquisition Corp. management to meet virtually with Roth Capital » 10:54 01/19/21 01/19 10:54 01/19/21 10:54 NBAC Newborn Acquisition Corp. $18.09 / +0.12 (+0.67%) Virtual Meetings to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Events NBAC Newborn Acquisition Corp. $18.09 / +0.12 (+0.67%) 12/16/20 Nuvve Corporation, IoTecha partner on EV charging solution 11/19/20 Nuvve, Lion Electric announce vehicle-to-grid collaboration 11/12/20 Newborn Acquisition Corp., Nuvve sign merger pact to take Nuvve public 01/25/21 Newborn Acquisition Corp. 01/26/21 Newborn Acquisition Corp. 01/27/21 Newborn Acquisition Corp.
Hot Stocks	Reading International trading halted, volatility trading pause 10:52 01/19/21 01/19 10:52 01/19/21 10:52
Recommendations	Yield10 Bioscience proof-of-concept validates pipeline, says H.C. Wainwright » 10:52 01/19/21 01/19 10:52 01/19/21 10:52 YTEN Yield10 Bioscience $15.01 / +1.51 (+11.19%) After Yield10 Bioscience… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly YTEN Yield10 Bioscience $15.01 / +1.51 (+11.19%) 08:43 Today Yield10 Bioscience achieves proof-of-concept milestone for PHA bioplastic 11/12/20 Yield10 Bioscience announces collaboration with Rothamsted Research 10/28/20 Yield10 Bioscience announces start of field tests of winter camelina varieties 10/01/20 Yield10 Bioscience completes harvesting for 2020 Field Test Program YTEN Yield10 Bioscience $15.01 / +1.51 (+11.19%) 09/10/20 H.C. Wainwright Yield10 Bioscience initiated with a Buy at H.C. Wainwright 08/27/20 National Securities Yield10 Bioscience upgraded to Buy from Neutral at National Securities YTEN Yield10 Bioscience $15.01 / +1.51 (+11.19%) 11/12/20 Yield10 Bioscience sees FY20 total net cash usage of $8.5M- $9.0M 11/12/20 Yield10 Bioscience reports Q3 EPS (87c), consensus (94c) 08/11/20 Yield10 Bioscience reports Q2 EPS (92c), consensus ($1.30) YTEN Yield10 Bioscience $15.01 / +1.51 (+11.19%) 11/12/20 Fly Intel: After-Hours Movers 08/24/20 Fly Intel: Pre-market Movers 08/11/20 Fly Intel: After-Hours Movers

Hot Stocks	Urban One trading halted, volatility trading pause 10:50 01/19/21 01/19 10:50 01/19/21 10:50 UONE Urban One $5.71 / -0.19 (-3.22%) ShowHide Related Items >><< Company News UONE Urban One $5.71 / -0.19 (-3.22%) 11/25/20 Urban One CEO buys 719K shares of common stock 08/31/20 Radio One awarded $431,900 contract modification from NIH 08/25/20 Urban One strength attributed to Washington Business Journal article
Recommendations	Merus price target raised to $32 from $19 at Roth Capital » 10:50 01/19/21 01/19 10:50 01/19/21 10:50 MRUS Merus $23.61 / +0.29 (+1.24%) , LLY Eli Lilly $195.53 / +4.68 (+2.45%) Roth Capital analyst Tony… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MRUS LLY MRUS Merus $23.61 / +0.29 (+1.24%) 06:37 Today Eli Lilly, Merus collaborate for novel T-cell re-directing bispecific antibodies 01/12/21 Merus in pacts with medical organizations in Netherlands and Japan for screening 01/07/21 Merus receives fast track designation for Zenocutuzumab from FDA 12/17/20 Merus, Sema4 enter into agreement for Phase 1/2 trial of zenocutuzumab LLY Eli Lilly $195.53 / +4.68 (+2.45%) 06:37 Today Eli Lilly, Merus collaborate for novel T-cell re-directing bispecific antibodies 01/15/21 Eli Lilly reports $30M limited partner investment in Unseen Capital Health Fund 01/11/21 Eli Lilly rises 12.5% 01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint MRUS LLY MRUS Merus $23.61 / +0.29 (+1.24%) 09/02/20 Roth Capital Roth Capital keeps Buy on Merus after delay of cancer data 06/26/20 H.C. Wainwright Merus initiated with a Buy at H.C. Wainwright 05/27/20 Fly Intel: Top five analyst downgrades 05/27/20 RBC Capital Merus downgraded to Sector Perform from Outperform at RBC Capital LLY Eli Lilly $195.53 / +4.68 (+2.45%) 09:52 Today Fly Intel: Top five analyst upgrades 06:14 Today Mizuho Eli Lilly upgraded to Buy from Neutral at Mizuho 01/12/21 Truist Eli Lilly price target raised to $200 from $182 at Truist 01/11/21 JPMorgan Alzheimer's data a 'significant positive' for Eli Lilly story, says JPMorgan MRUS LLY MRUS Merus $23.61 / +0.29 (+1.24%) 08/06/20 Merus reports Q2 EPS (54c), consensus (61c) LLY Eli Lilly $195.53 / +4.68 (+2.45%) 12/15/20 Eli Lilly sees FY21 EPS $7.75-$8.40, consensus $8.07 12/15/20 Eli Lilly raises FY20 EPS view to $7.45-$7.65 from $7.20-$7.40, consensus $7.32 12/02/20 Eli Lilly says updated purchase of LY-CoV555 to boost FY20 EPS view by 25c 10/27/20 Eli Lilly backs FY20 adj. EPS view $7.20-$7.40, consensus $7.28 LLY LLY Eli Lilly $195.53 / +4.68 (+2.45%) 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports MRUS LLY MRUS Merus $23.61 / +0.29 (+1.24%) 01/07/21 Fly Intel: After-Hours Movers 09/14/20 Fly Insider: Karuna, DexCom among weeks notable insider trades LLY Eli Lilly $195.53 / +4.68 (+2.45%) 01/11/21 Fly Intel: Wall Street's top stories for Monday 01/11/21 Fly Intel: Wall Street's top stories at midday 01/11/21 Eli Lilly and Alzheimer's research peers jump after study meets endpoint 01/11/21 Fly Intel: Pre-market Movers 01/26/21 Pharmacovigilance & Risk Management Strategies Virtual Conference 01/28/21 IASLC Virtual World Conference on Lung Cancer 01/29/21 Eli Lilly - LLY LLY LLY Eli Lilly $195.53 / +4.68 (+2.45%) 01/15/21 Eli Lilly call volume above normal and directionally bullish 01/13/21 Early notable gainers among liquid option names on January 13th 01/11/21 Early notable gainers among liquid option names on January 11th 12/09/20 Early notable gainers among liquid option names on December 9th
Conference/Events	G1 Therapeutics management to meet virtually with Roth Capital » 10:49 01/19/21 01/19 10:49 01/19/21 10:49 GTHX G1 Therapeutics $21.00 / +0.18 (+0.86%) Virtual Meeting to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events GTHX G1 Therapeutics $21.00 / +0.18 (+0.86%) 12/09/20 G1 Therapeutics says trilaciclib showed improved OS in Phase 2 trial 11/18/20 G1 Therapeutics to present clinical data on trilaciclib, rintodestrant 09/30/20 G1 Therapeutics CEO Mark Velleca to move to new role, John Bailey to succeed 08/17/20 G1 Therapeutics announces FDA acceptance of trilaciclib NDA GTHX G1 Therapeutics $21.00 / +0.18 (+0.86%) 11/17/20 Raymond James Raymond James downgrades G1 Therapeutics after removing rintodestrant from model 11/17/20 Raymond James G1 Therapeutics downgraded to Outperform from Strong Buy at Raymond James 07/01/20 Wedbush G1 Therapeutics price target lowered to $50 from $55 at Wedbush 06/26/20 Roth Capital G1 Therapeutics initiated with a Buy at Roth Capital GTHX G1 Therapeutics $21.00 / +0.18 (+0.86%) 11/04/20 G1 Therapeutics sees ending year with cash, cash equivalents of $200M-$205M 11/04/20 G1 Therapeutics reports Q3 EPS (31c), consensus (30c) 08/05/20 G1 Therapeutics reports Q2 EPS (83c), consensus (83c) 02/15/21 PDUFA Date for Trilaciclib 01/20/21 G1 Therapeutics
Downgrade	Xerox downgraded to Sell at Cross Research on work from home headwinds » 10:48 01/19/21 01/19 10:48 01/19/21 10:48 XRX Xerox $21.60 / -0.89 (-3.96%) Cross Research analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options XRX Xerox $21.60 / -0.89 (-3.96%) 12/11/20 Xerox announces Xavier Heiss as CFO 11/13/20 Icahn reduces stake in Herbalife, boosts stake in Xerox 10/22/20 DARPA awards Xerox unit PARC contract to expand ocean knowledge 09/11/20 Xerox announces departure of CFO William Osbourn XRX Xerox $21.60 / -0.89 (-3.96%) 09:58 Today Cross Research Xerox downgraded to Sell from Hold at Cross Research 12/16/20 Morgan Stanley Xerox price target raised to $24 from $17 at Morgan Stanley 10/13/20 Morgan Stanley Morgan Stanley upgrades IT Hardware industry view to Attractive from In-Line 07/24/20 Fly Intel: Top five analyst downgrades XRX Xerox $21.60 / -0.89 (-3.96%) 10/27/20 Xerox reports Q3 adjusted EPS 48c, consensus 24c 07/28/20 Xerox reports Q2 EPS 15c, consensus (7c) XRX Xerox $21.60 / -0.89 (-3.96%) 11/09/20 Fly Insider: Xerox, At Home Group among week's notable insider trades 08/19/20 Fly Intel: After-Hours Movers 08/10/20 Fly Insider: Axis Capital, Carvana among week's notable insider trades XRX Xerox $21.60 / -0.89 (-3.96%) 12/02/20 Largest borrow rate increases among liquid names 11/13/20 Early notable gainers among liquid option names on November 13th 09/22/20 Unusual call flow in option market yesterday 09/21/20 Heavy call volume in Xerox as shares slide 5%
Options	Taiwan Semi call volume above normal and directionally bullish » 10:45 01/19/21 01/19 10:45 01/19/21 10:45 TSM TSMC $133.54 / +8.28 (+6.61%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options TSM TSMC $133.54 / +8.28 (+6.61%) 01/14/21 TSMC sees FY21 CapEx $25B-$28B 01/08/21 TSMC reports December revenue NT$117.37B, up 13.6% y/y 11/10/20 TSMC reports October revenue NT$119.3B, up 12.5% y/y 10/08/20 TSMC reports September revenue NT$127.59B, up 24.9% y/y TSM TSMC $133.54 / +8.28 (+6.61%) 01/14/21 Needham Intel upgraded to Buy from Hold at Needham 01/12/21 Fly Intel: Top five analyst upgrades 01/12/21 Bernstein TSMC upgraded to Outperform from Market Perform at Bernstein 12/29/20 RBC Capital Intel intraday move on Third Point news looks 'overdone,' says RBC Capital TSM TSMC $133.54 / +8.28 (+6.61%) 01/14/21 TSMC sees Q1 revenue $12.7B-$13B, consensus $12.62B 01/14/21 TSMC reports Q4 EPS 97c, consensus 94c 10/15/20 TSMC sees Q4 revenue $12.4B-$12.7B, consensus $11.71B 10/15/20 TSMC reports Q3 EPS 90c, consensus 77c TSM TSMC $133.54 / +8.28 (+6.61%) 06:29 Today TSMC, UMC to see full capacity utilization for 28nm through Q3, DigiTimes says 01/14/21 TSMC pledges to fix global auto chip shortage, FT reports 01/12/21 Intel plans to outsource production of new chips to TSMC, Reuters reports 01/08/21 Intel has talked with TSMC, Samsung about outsourcing chips, Bloomberg reports TSM TSMC $133.54 / +8.28 (+6.61%) 01/14/21 AMD slips as analyst says sell on Gelsinger's return to Intel 01/14/21 Shopify, Intel upgrades among today's top calls on Wall Street 01/14/21 Fly Intel: Pre-market Movers 07/24/20 Fly Intel: Wall Street's top stories for Friday TSM TSMC $133.54 / +8.28 (+6.61%) 12/15/20 Taiwan Semi call volume above normal and directionally bullish 12/11/20 Unusual call flow in option market yesterday 12/10/20 Call sale in Taiwan Semiconductor exits short-term trade for $3.2M loss 12/04/20 Taiwan Semi call volume above normal and directionally bullish

General news	8-Week Bill Announcement to be released at 11:00 10:45 01/19/21 01/19 10:45 01/19/21 10:45
General news	4-Week Bill Announcement to be released at 11:00 10:45 01/19/21 01/19 10:45 01/19/21 10:45
General news	4-Week Bill Announcement to be released at 11:00 10:45 01/19/21 01/19 10:45 01/19/21 10:45
General news	8-Week Bill Announcement to be released at 11:00 10:45 01/19/21 01/19 10:45 01/19/21 10:45
Conference/Events	Zoetis management to meet virtually with William Blair » 10:40 01/19/21 01/19 10:40 01/19/21 10:40 ZTS Zoetis $163.52 / +2.59 (+1.61%) Virtual Meeting to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events ZTS Zoetis $163.52 / +2.59 (+1.61%) 12/09/20 Zoetis raises quarterly dividend by 25% to 25c per share 11/12/20 Zoetis receives European Commissionmarketing authorization for Librela ZTS Zoetis $163.52 / +2.59 (+1.61%) 11/12/20 Truist Zoetis price target raised to $170 from $160 at Truist 11/06/20 Barclays Zoetis price target raised to $189 from $175 at Barclays 09/21/20 Atlantic Equities Zoetis initiated with an Overweight at Atlantic Equities 08/18/20 Argus Elanco price target raised to $30 from $26 at Argus ZTS Zoetis $163.52 / +2.59 (+1.61%) 11/05/20 Zoetis sees FY20 EPS $3.76-$3.81 , consensus $3.64 11/05/20 Zoetis reports Q3 EPS $1.10, consensus 91c 11/04/20 Notable companies reporting before tomorrow's open 11/04/20 Notable companies reporting before tomorrow's open ZTS Zoetis $163.52 / +2.59 (+1.61%) 09/12/20 Elanco stock well positioned for gains, Barron's says 08/15/20 Pet business keeps running strong, Barron's says 02/16/21 Zoetis - ZTS 00:00 Today Zoetis

Hot Stocks	Aclaris Therapeutics trading resumes 10:40 01/19/21 01/19 10:40 01/19/21 10:40 ACRS Aclaris Therapeutics $15.44 / +9.58 (+163.48%) ShowHide Related Items >><< Company News Earnings On The Fly Events ACRS Aclaris Therapeutics $15.44 / +9.58 (+163.48%) 10:35 Today Aclaris Therapeutics trading halted, volatility trading pause 07:07 Today Aclaris Therapeutics announces topline data from Phase 2a trial of ATI-450 11/04/20 Aclaris continues to pursue strategic alternatives, including seeking partners 11/04/20 Aclaris Therapeutics expects to submit investigational NDA for ATI-2138 in 2021 ACRS Aclaris Therapeutics $15.44 / +9.58 (+163.48%) 11/04/20 Aclaris Therapeutics reports Q3 EPS (25c), consensus (30c) 08/07/20 Aclaris Therapeutics reports Q2 EPS (28c), consensus (36c) ACRS Aclaris Therapeutics $15.44 / +9.58 (+163.48%) 09:17 Today Fly Intel: Pre-market Movers 08:00 Today Aclaris Therapeutics - ACRS
Hot Stocks	Greenrose Axquisition Corporation (Units) trading resumes 10:38 01/19/21 01/19 10:38 01/19/21 10:38
Hot Stocks	Aclaris Therapeutics trading halted, volatility trading pause 10:35 01/19/21 01/19 10:35 01/19/21 10:35 ACRS Aclaris Therapeutics $14.95 / +9.09 (+155.12%) ShowHide Related Items >><< Company News Earnings On The Fly Events ACRS Aclaris Therapeutics $14.95 / +9.09 (+155.12%) 07:07 Today Aclaris Therapeutics announces topline data from Phase 2a trial of ATI-450 11/04/20 Aclaris continues to pursue strategic alternatives, including seeking partners 11/04/20 Aclaris Therapeutics expects to submit investigational NDA for ATI-2138 in 2021 11/04/20 Aclaris Therapeutics files orphan drug designation for ATI-450-CAPS-201 ACRS Aclaris Therapeutics $14.95 / +9.09 (+155.12%) 11/04/20 Aclaris Therapeutics reports Q3 EPS (25c), consensus (30c) 08/07/20 Aclaris Therapeutics reports Q2 EPS (28c), consensus (36c) ACRS Aclaris Therapeutics $14.95 / +9.09 (+155.12%) 09:17 Today Fly Intel: Pre-market Movers 08:00 Today Aclaris Therapeutics - ACRS
General news	FX Action: USD-JPY » 10:35 01/19/21 01/19 10:35 01/19/21 10:35 FX Action: USD-JPY has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Hot Stocks	General Dynamics awarded $695M U.S. Army Europe contract » 10:34 01/19/21 01/19 10:34 01/19/21 10:34 GD General Dynamics $154.53 / +1.28 (+0.84%) General Dynamics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events GD General Dynamics $154.53 / +1.28 (+0.84%) 12/28/20 House of Reps votes 322 to 87 to override Trump's defense bill veto 12/23/20 General Dynamics awarded $4.6B Army contract for battle tanks 12/18/20 General Dynamics awarded $4.62B Army contract to produce Abrams tanks 12/17/20 Trump says will veto defense bill over Section 230 GD General Dynamics $154.53 / +1.28 (+0.84%) 11/03/20 Morgan Stanley Morgan Stanley sees attractive buying opportunity in Defense stocks 10/29/20 Credit Suisse General Dynamics price target lowered to $140 from $156 at Credit Suisse 10/02/20 Fly Intel: Top five analyst downgrades 10/02/20 Baird Baird downgrades General Dynamics, sees no 'material' Gulfstream ramp GD General Dynamics $154.53 / +1.28 (+0.84%) 10/28/20 General Dynamics reports Q3 EPS $2.90, consensus $2.86 10/27/20 Notable companies reporting before tomorrow's open 10/27/20 Notable companies reporting before tomorrow's open 07/29/20 General Dynamics lowers FY20 EPS view to $11.00-$11.10 from $11.30-$11.40 GD General Dynamics $154.53 / +1.28 (+0.84%) 01/02/21 Congress overturns Trump veto on Defense bill, NPR reports 08/10/20 General Dynamics unit reaches deal to end strike, Reuters reports GD General Dynamics $154.53 / +1.28 (+0.84%) 01/02/21 Week in review: How Trump's policies moved stocks 12/26/20 Week in review: How Trump's policies moved stocks 12/19/20 Week in review: How Trump's policies moved stocks 09/17/20 CVS initiation, Stitch Fix upgrade among today's top calls on Wall Street 01/27/21 General Dynamics - GD

Hot Stocks	Alpha short Mesoblast, expects chronic lower back pain Phase 3 trial to fail » 10:33 01/19/21 01/19 10:33 01/19/21 10:33 MESO Mesoblast $9.48 / -0.21 (-2.17%) Alpha Exposure said in a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options MESO Mesoblast $9.48 / -0.21 (-2.17%) 01/11/21 Mesoblast announces additional results from DREAM-HF trial 12/17/20 Mesoblast's COVID remestemcel trial not likely to meet mortality reduction goal 12/15/20 Mesoblast trading halted, news pending 12/14/20 Mesoblast reports topline results from DREAM-HF Phase 3 trial MESO Mesoblast $9.48 / -0.21 (-2.17%) 08:01 Today Jefferies Mesoblast downgraded to Hold from Buy at Jefferies 12/22/20 Fly Intel: Top five analyst downgrades 12/22/20 Maxim Mesoblast downgraded to Hold from Buy at Maxim 12/18/20 H.C. Wainwright Mesoblast price target lowered to $16 from $20 at H.C. Wainwright MESO Mesoblast $9.48 / -0.21 (-2.17%) 11/19/20 Mesoblast reports Q3 EPS ($4.21), two estimates (26c) 08/26/20 Notable companies reporting after market close MESO Mesoblast $9.48 / -0.21 (-2.17%) 01/11/21 Fly Intel: Wall Street's top stories for Monday 01/11/21 Fly Intel: Wall Street's top stories at midday 01/11/21 Fly Intel: Pre-market Movers 12/15/20 Fly Intel: Wall Street's top stories for Tuesday MESO Mesoblast $9.48 / -0.21 (-2.17%) 01/11/21 Unusually active option classes on open January 11th 12/22/20 Largest borrow rate increases among liquid names 12/15/20 Largest borrow rate increases among liquid names 12/11/20 Largest borrow rate increases among liquid names
Hot Stocks	Greenrose Axquisition Corporation (Units) trading halted, volatility trading pause 10:33 01/19/21 01/19 10:33 01/19/21 10:33
Hot Stocks	State Street sees Q1 NII down about 68% sequentially » 10:26 01/19/21 01/19 10:26 01/19/21 10:26 STT State Street $74.47 / -2.815 (-3.64%) Expects NII to stabilize… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events STT State Street $74.47 / -2.815 (-3.64%) 10:26 Today State Street sees Q1 fee revenue down y/y by low single digits 10:23 Today State Street board reinitiates share repurchase program of up to $475M in Q1 10:16 Today State Street faced 'a number of unprecedented challenges' in 2020 08:33 Today State Street affirms medium-term targets, sees revenue growth 4%-5% with CRD STT State Street $74.47 / -2.815 (-3.64%) 01/11/21 Piper Sandler State Street price target raised to $81 from $69 at Piper Sandler 01/05/21 Wolfe Research State Street downgraded to Underperform from Peer Perform at Wolfe Research 01/05/21 Goldman Sachs State Street downgraded to Neutral from Buy at Goldman Sachs 01/05/21 Goldman Sachs Northern Trust downgraded to Sell from Neutral at Goldman Sachs STT State Street $74.47 / -2.815 (-3.64%) 07:44 Today State Street reports Q4 EPS $1.39, consensus $1.56 10/16/20 State Street reports Q3 EPS $1.45, consensus $1.41 10/15/20 Notable companies reporting before tomorrow's open 10/15/20 Notable companies reporting before tomorrow's open STT State Street $74.47 / -2.815 (-3.64%) 12/11/20 State Street weighs strategic options for asset management unit, Bloomberg says 12/11/20 State Street weighs strategic options for asset management unit, Bloomberg says STT State Street $74.47 / -2.815 (-3.64%) 11/30/20 Apple upgrade, Slack downgrade among today's top calls on Wall Street 10/16/20 Fly Intel: Pre-market Movers 02/24/21 22nd Annual Virtual Financial Services Forum 10:00 Today State Street - STT
Hot Stocks	State Street sees Q1 fee revenue down y/y by low single digits 10:26 01/19/21 01/19 10:26 01/19/21 10:26 STT State Street $74.63 / -2.655 (-3.44%) ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events STT State Street $74.63 / -2.655 (-3.44%) 10:23 Today State Street board reinitiates share repurchase program of up to $475M in Q1 10:16 Today State Street faced 'a number of unprecedented challenges' in 2020 08:33 Today State Street affirms medium-term targets, sees revenue growth 4%-5% with CRD 08:32 Today State Street sees FY21 NII down 14%-17% STT State Street $74.63 / -2.655 (-3.44%) 01/11/21 Piper Sandler State Street price target raised to $81 from $69 at Piper Sandler 01/05/21 Wolfe Research State Street downgraded to Underperform from Peer Perform at Wolfe Research 01/05/21 Goldman Sachs State Street downgraded to Neutral from Buy at Goldman Sachs 01/05/21 Goldman Sachs Northern Trust downgraded to Sell from Neutral at Goldman Sachs STT State Street $74.63 / -2.655 (-3.44%) 07:44 Today State Street reports Q4 EPS $1.39, consensus $1.56 10/16/20 State Street reports Q3 EPS $1.45, consensus $1.41 10/15/20 Notable companies reporting before tomorrow's open 10/15/20 Notable companies reporting before tomorrow's open STT State Street $74.63 / -2.655 (-3.44%) 12/11/20 State Street weighs strategic options for asset management unit, Bloomberg says 12/11/20 State Street weighs strategic options for asset management unit, Bloomberg says STT State Street $74.63 / -2.655 (-3.44%) 11/30/20 Apple upgrade, Slack downgrade among today's top calls on Wall Street 10/16/20 Fly Intel: Pre-market Movers 02/24/21 22nd Annual Virtual Financial Services Forum 10:00 Today State Street - STT
Options	XPeng call volume above normal and directionally bullish » 10:25 01/19/21 01/19 10:25 01/19/21 10:25 XPEV Xpeng $54.20 / +6.37 (+13.32%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options XPEV Xpeng $54.20 / +6.37 (+13.32%) 01/15/21 Xpeng unveils beta version of Navigation Guided Pilot autonomous driving system 01/11/21 Telenav to provide connected navigation for Xpeng customers in Europe 01/03/21 Xpeng announces vehicle delivery results for December 2020 01/03/21 Xpeng partners with lidar maker Livox XPEV Xpeng $54.20 / +6.37 (+13.32%) 07:11 Today Jefferies Xpeng initiated with a Hold at Jefferies 01/04/21 Citi Xpeng partnership with Livox is 'very positive,' says Citi 12/21/20 Wedbush Tesla price target raised to $715 from $560 at Wedbush 12/14/20 Fly Intel: Top five analyst initiations XPEV Xpeng $54.20 / +6.37 (+13.32%) 11/12/20 Xpeng sees Q4 revenue RMB 2.2B, up 244% year-over-year 11/12/20 Xpeng reports Q3 EPS (32c), deliveries of 8,578 09 Dec 27 Aug XPEV Xpeng $54.20 / +6.37 (+13.32%) 12/12/20 Nio, Xeng, Li Auto not the next Tesla, Barron's says 12/02/20 House approves bill restricting Chinese firms on U.S exchanges, Bloomberg says 12/01/20 Lucid Motors finishes 1st part of construction on Arizona factory, Electrek says XPEV Xpeng $54.20 / +6.37 (+13.32%) 10:05 Today Facebook upgrade, Roku initiation among today's top calls on Wall Street 12/21/20 Tesla under pressure on first trading day on S&P 500 Index 12/21/20 Microsoft, Walmart upgrades among today's top calls on Wall Street 12/19/20 Charged: Deutsche sees multiple EV winners, says buy Xpev XPEV Xpeng $54.20 / +6.37 (+13.32%) 01/12/21 XPeng call volume above normal and directionally bullish 12/31/20 XPeng call volume above normal and directionally bullish 12/29/20 XPeng call volume above normal and directionally bullish 12/15/20 XPeng call volume above normal and directionally bullish

Events

Earnings calls, analyst events, roadshows and more

Today at 11:30

3-Month Bill Auction Government Event
Today at 11:30

6-Month Bill Auction Government Event
Today at 12:00

Jason Furman & Larry Summer Government Event

Virtual Evemt
SGRP
Today at 12:00

SPAR Group, Inc. Firm Sponsored Meetings
EIDX
Today at 12:00

Eidos Therapeutics, Inc. Firm Sponsored Meetings
Today at 12:00

Telecom Services & Media Industry Meetings
Today at 12:00

Pharma / Biotech Industry Meetings
CBIO
Today at 13:00

Catalyst Biosciences - CBIO Conference Calls
BBIO
Today at 13:00

BridgeBio Pharma, Inc. Firm Sponsored Meetings
HALO
Today at 15:00

Halozyme - HALO Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	TCRR X TCRR TCR2 Therapeutics Secondary Managers: Goldman Sachs, Jefferies, Piper Sandler & BMO Capital $ Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	DFH X DFH Dream Finders Homes IPO Managers: BofA, RBC Capital & BTIG, Builder Advisor, Zelman, TCB Capital, Wedbush $12.00-15.00 9.6M Shares MYTE X MYTE Mytheresa IPO Managers: Morgan Stanley & JPMorgan, Credit Suisse, UBS, Jefferies, Cowen $16.00-18.00 15.647M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DYN X DYN Dyne Therapeutics Secondary Managers: JPMorgan, Jefferies, Piper Sandler & Stifel $28.61 5.5M Shares
Thurs	PAX X PAX Patria IPO Managers: JPMorgan, BofA & Credit Suisse, Goldman Sachs, Bradesco BBI, BTG Pactual, ITAU, Keefe Bruyette, Santander, XP $14.00-16.00 26.65M Shares
Fri	No deals

View All Syndicate Announcements »

Semtech reports Q3 EPS 47c, consensus 46c

TODAY'S FREE FLY STORIES

Get Full Fly Access